NMN Results: What the Trials Measured vs. What Users Report

"What results does NMN give?" and "how long does NMN take?" get asked in the same breath, but they are different questions and they have different answers. The clock question — when the biomarker moves, when it is fair to judge — belongs on our page about how long NMN takes to work. This page answers the other one: when the trials looked, what did they actually find?

That distinction matters because the honest answer is uncomfortable. Every human NMN trial with a blood measurement found the same result, and it is a laboratory value. The results people are shopping for — energy, focus, a younger-looking face, a body that behaves like it did ten years ago — were either measured and not found, or never measured at all. Below is the trial-by-trial record, followed by the gap between it and the testimonials.

The one result every NMN trial found

Oral NMN raises NAD+ in blood. That part is settled and replicated. A dose-ranging randomized trial gave 80 healthy middle-aged adults placebo, 300, 600 or 900 mg once daily for 60 days and found blood NAD significantly higher than both baseline and placebo in every NMN group at day 30 and day 60 ¹. A 12-week placebo-controlled trial of 250 mg/day in 30 healthy subjects found whole-blood NAD+ significantly increased ². A trial giving 250 mg/day to older men for 6 or 12 weeks reported the same rise in NAD+ and its metabolites ³.

Hold on to how narrow that is. It is a concentration in a blood tube. Nobody feels it, nobody sees it in a mirror, and — as the rest of this page shows — it does not reliably carry anything else with it.

What each trial actually measured, and what it found

The interesting detail is not that NMN trials exist. It is what each one chose to measure and where its own numbers landed. Read as a set, the pattern is that the biomarker moves, a scattering of secondary measures move, and the endpoints the researchers themselves nominated as primary often do not.

The dose-ranging trial (80 adults, 60 days). Alongside the NAD+ rise, six-minute walking distance increased more in the 300, 600 and 900 mg groups than placebo at both day 30 and day 60, and self-reported health on the SF-36 questionnaire improved. HOMA-IR — a standard insulin-resistance index — showed no significant difference from placebo at day 60 ¹. The trial also reported that "blood biological age" rose in the placebo group and stayed unchanged on NMN; that figure came from the Aging.Ai 3.0 calculator, which converts routine blood values into an age estimate. It is a calculator output, not a measurement of how old anyone is. Note also the disclosures: the trial's first author was an employee of a commercial NMN company, and two co-authors were employees of a chemicals manufacturer ¹.

The 12-week 250 mg trial (30 subjects). Whole-blood NAD+ went up. So did nicotinic acid mononucleotide — but blood NMN itself did not, which is a useful reminder that the capsule does not simply appear in your bloodstream as NMN ². This trial's job was safety, and it reported no abnormalities in physiological and laboratory testing.

The older-men trial (250 mg/day, 6 or 12 weeks). NAD+ and its metabolites rose. The authors described "nominally significant" improvements in gait speed and left-grip performance, and said in the abstract itself that these should be validated in larger studies. Body composition did not change ³. When a paper flags its own positive finding as needing replication, that flag belongs in the summary, not in a product page's fine print.

The walking-and-sleep trial (60 older adults, 250 mg/day, 12 weeks). This is the one worth reading closely, because it is quoted everywhere for its walking and sleep results. Its primary outcome was a stepping test, and there was no significant difference between NMN and placebo at either 4 or 12 weeks. The results people cite were secondary: at 12 weeks the NMN group had a shorter 4-meter walking time, higher blood NAD+ and its metabolites, and lower scores for "Daytime dysfunction" and "Global PSQI" on the Pittsburgh Sleep Quality questionnaire ⁴. A missed primary endpoint with positive secondaries is a hypothesis worth testing again, not a proven result.

The morning-versus-afternoon sleep trial (108 older adults, 250 mg/day, 12 weeks). Participants were split four ways — NMN in the morning, NMN in the afternoon, and two matching placebo groups. Five-times sit-to-stand improved after the intervention in all four groups, and drowsiness improved in both afternoon groups — the placebo afternoon group included. The largest effect sizes were in the afternoon NMN group ⁵. That is exactly the shape of result that a testimonial cannot distinguish from an effect, and a placebo arm can.

The runners' trial (48 amateur runners, 6 weeks, plus training). This is where a widely repeated claim goes wrong. Oxygen uptake and power at the first and second ventilatory thresholds increased more in the 600 and 1200 mg groups than in control. But VO2 max itself did not differ, and neither did oxygen pulse or peak power ⁶. So "NMN raised VO2 max in runners" reverses what the paper reported. Everyone in the trial was also training five to six times a week.

The insulin-sensitivity trial (prediabetic women). NMN increased insulin-stimulated glucose disposal measured by clamp, along with muscle insulin signaling and expression of remodeling-related genes ⁷. It is a genuine result in a specific population, and it was publicly contested by another researcher who questioned its strength and interpretation ⁸.

The 28-day pharmaceutical-grade trial (30 overweight or obese adults, 45 and older). Here NAD+ augmentation did produce cardiometabolic movement: body weight, diastolic blood pressure, total cholesterol and LDL cholesterol all fell more than placebo. In the same 30 people, muscle strength, muscle fatigability, aerobic capacity and stair-climbing power did not differ between groups, and insulin sensitivity and liver and intra-abdominal fat did not change in either group ⁹. Several of the authors worked for the company developing the compound ⁹. It is the most promising set of numbers on this page and it is 28 days long in 30 people.

The pooled verdict

Individual trials are noisy; the pooled analyzes are the tiebreaker, and they are blunt. A 2025 systematic review and meta-analysis of randomized trials in adults with a mean age over 60 found NMN had no significant effect on skeletal muscle index, handgrip strength, gait speed or the five-time chair-stand test, and its narrative synthesis found no improvement in knee-extension strength, the short physical performance battery or thigh muscle mass. Its conclusion: current evidence does not support NMN for preserving muscle mass and function in this age group ¹⁰.

A 2024 meta-analysis pooled eight randomized trials — doses from 250 to 2000 mg/day, durations from 14 days to 12 weeks, 342 mostly non-diabetic middle-aged and older adults — and found no significant benefit on fasting glucose, fasting insulin, glycated hemoglobin, HOMA-IR or lipid profile ¹¹.

And a 2026 PRISMA-guided systematic review that screened 113 eligible studies, 33 of them human intervention studies, reached the summary sentence this whole site is built around: oral NR and NMN consistently demonstrate biochemical target engagement and are generally well tolerated, while effects on functional, metabolic and vascular outcomes are heterogeneous and often null or endpoint-specific ¹².

What buyers report that no trial measured

Now put the testimonials next to that record. The four results most often described in NMN reviews are more energy, sharper focus or less brain fog, better skin, and better sleep. Only the last of those has any trial hook at all, and it is a secondary, questionnaire-based finding in older adults — in a study whose primary endpoint missed ⁴, and in a study where the afternoon placebo group's drowsiness improved too ⁵.

The others were not measured and then found absent. In the trials on this page, they were largely not measured at all. There is no NMN trial here with a skin endpoint, none with a brain-fog endpoint, and the closest thing to an energy endpoint is a fatigue questionnaire or a walking test. So a review saying "my energy transformed" is not contradicting the evidence — it is describing something the evidence never went looking for. We take the energy claim apart on its own terms in does NAD+ actually boost energy?.

That is the honest frame for a felt result: it is unmeasured, it is among the most placebo-responsive categories in medicine, and it arrives at exactly the moment you have spent money and started paying attention to how you feel.

"NMN before and after"

Searches for NMN before-and-after pictures are looking for a visible change, and it is worth saying plainly what the record supports. Of everything above, one measured outcome would show up in a photograph — the roughly 1.9 kg mean weight difference over 28 days in the pharmaceutical-grade trial ⁹ — and that trial also found no change in liver or intra-abdominal fat. Nothing here measured skin, hair or face. The broader photo-gallery problem, including why the IV versions are the least reliable of all, is covered in NAD+ before and after: what results are realistic?.

What a realistic result looks like

If you are deciding whether to buy, the defensible expectation is this: your blood NAD+ will very likely rise, you will not feel that happen, and whether anything follows it is unsettled in a way the pooled evidence leans against rather than toward. Judge over roughly 8 to 12 weeks — the window the positive trials used — and judge against how you were before you started paying attention, not against how you hoped to feel.

The reason this site keeps saying "the biomarker is not the result" is that the trials keep proving it. Blood NAD+ rose in the muscle trials that found nothing ¹⁰, in the metabolic trials that found nothing ¹¹, and in the review that pooled 33 human studies and called the outcomes heterogeneous and often null ¹². A number going up is the beginning of the argument, not the end of it.

Bottom line

NMN's replicated result is a rise in blood NAD+, confirmed by the first checkpoint in every trial that measured it ¹²³. Past that, the record is a scatter: a missed primary endpoint with positive walking and sleep secondaries ⁴, improvements that also appeared in an afternoon placebo group ⁵, threshold-power gains without a VO2 max change in runners who were also training ⁶, a contested insulin-sensitivity finding ⁷⁸, and a 28-day cardiometabolic signal in 30 people ⁹ — set against pooled analyzes that found nothing for muscle, function, glucose or lipids ¹⁰¹¹¹². For the timing question, see how long NMN takes to work; for the "does it work at all" question, does NMN actually work?; for how NMN compares with the other oral precursor, NMN vs NR. If you decide the bet is worth making anyway, choose on purity and verification in the best NMN supplements, rated by evidence, take the dose the trials actually used, and read the reasons people stop taking NMN before you commit. The whole category sits in context in our pillar guide to the NAD+ evidence.

This is consumer education, not medical advice. NMN is sold as a dietary supplement and is not approved to treat, prevent or cure any condition. Talk to a clinician before starting it, especially if you take medications or have a medical condition.